CHMP recommends extension of approval of Lucentis to treatment of proliferative diabetic retinopathy.- Novartis
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Lucentis. The marketing authorisation holder for this medicinal product is Novartis Europharm Limited.
The CHMP adopted an extension to the existing indication to add the treatment of proliferative diabetic retinopathy (PDR).For information, the indication for Lucentis will be as follows:�Lucentis is indicated in adults for: The treatment of proliferative diabetic retinopathy (PDR)".
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.